These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. Janssen I; Chen CC; Millo CM; Ling A; Taieb D; Lin FI; Adams KT; Wolf KI; Herscovitch P; Fojo AT; Buchmann I; Kebebew E; Pacak K Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1784-91. PubMed ID: 26996779 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519 [TBL] [Abstract][Full Text] [Related]
13. Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway. Klingenstein A; Haug AR; Miller C; Hintschich C Orbit; 2015 Feb; 34(1):16-22. PubMed ID: 25264824 [TBL] [Abstract][Full Text] [Related]
14. The added value of Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022 [TBL] [Abstract][Full Text] [Related]
15. Performance of Han S; Suh CH; Woo S; Kim YJ; Lee JJ J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341 [TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Naji M; Zhao C; Welsh SJ; Meades R; Win Z; Ferrarese A; Tan T; Rubello D; Al-Nahhas A Mol Imaging Biol; 2011 Aug; 13(4):769-75. PubMed ID: 20700766 [TBL] [Abstract][Full Text] [Related]
17. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108 [TBL] [Abstract][Full Text] [Related]
18. Comparison of Patil VA; Goroshi MR; Shah H; Malhotra G; Hira P; Sarathi V; Lele VR; Jadhav S; Lila A; Bandgar TR; Shah NS World J Nucl Med; 2020; 19(2):99-105. PubMed ID: 32939195 [TBL] [Abstract][Full Text] [Related]
19. The Utility of Jaiswal SK; Sarathi V; Malhotra G; Verma P; Hira P; Badhe P; Memon SS; Barnabas R; Patil VA; Anurag ; Lila R; Shah NS; Bandgar T Indian J Endocrinol Metab; 2021; 25(5):410-417. PubMed ID: 35300451 [TBL] [Abstract][Full Text] [Related]
20. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer. Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]